Eli Lilly and Company $LLY Stock Purchased by Edgemoor Investment Advisors Inc.

Edgemoor Investment Advisors Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 10.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,137 shares of the company’s stock after acquiring an additional 1,105 shares during the quarter. Edgemoor Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $14,043,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in LLY. Means Investment CO. Inc. grew its position in Eli Lilly and Company by 3.1% during the 3rd quarter. Means Investment CO. Inc. now owns 4,872 shares of the company’s stock worth $5,637,000 after acquiring an additional 146 shares during the last quarter. Paragon Advisors LLC increased its holdings in Eli Lilly and Company by 16.6% in the 3rd quarter. Paragon Advisors LLC now owns 4,706 shares of the company’s stock worth $5,445,000 after purchasing an additional 669 shares in the last quarter. M Holdings Securities Inc. bought a new position in Eli Lilly and Company in the third quarter valued at about $9,595,000. Avantax Planning Partners Inc. raised its position in Eli Lilly and Company by 1.4% in the third quarter. Avantax Planning Partners Inc. now owns 6,772 shares of the company’s stock valued at $7,835,000 after purchasing an additional 94 shares during the last quarter. Finally, American State Bank Iowa raised its position in Eli Lilly and Company by 9.8% in the third quarter. American State Bank Iowa now owns 348 shares of the company’s stock valued at $403,000 after purchasing an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,372.15 on Monday. The stock has a market cap of $1.29 trillion, a price-to-earnings ratio of 44.54, a P/E/G ratio of 1.62 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00. The company’s fifty day moving average is $1,215.24 and its 200 day moving average is $1,101.16. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. Eli Lilly and Company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period last year, the company earned $7.02 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Guggenheim lifted their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Truist Financial reaffirmed a “buy” rating and issued a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. Scotiabank raised their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. UBS Group raised their price objective on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,404.14.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.